坎地沙坦治疗偏头痛：范围回顾。

IF 3.6 4区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical therapeutics Pub Date : 2025-09-01 DOI:10.1016/j.clinthera.2025.06.003

Ena Elizabeth L. Naoe MD , Mykha Marie B. Tabuzo MD , Roland Dominic G. Jamora MD, PhD

{"title":"坎地沙坦治疗偏头痛：范围回顾。","authors":"Ena Elizabeth L. Naoe MD , Mykha Marie B. Tabuzo MD , Roland Dominic G. Jamora MD, PhD","doi":"10.1016/j.clinthera.2025.06.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Migraine is a prevalent and debilitating disorder, ranked as the third leading cause of global disability. Given its significant health and financial impact, exploring alternative treatments is crucial. Candesartan, an angiotensin-receptor blocker, has shown potential as a management for migraine.</div></div><div><h3>Methods</h3><div>A scoping review of literature on the efficacy and safety of candesartan in migraine treatment was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Scoping Reviews guidelines.</div></div><div><h3>Findings</h3><div>Thirty-eight articles were included in this review. Candesartan has shown promising results in preventing migraine, particularly in patients with comorbid conditions such as hypertension. Its mechanism may involve modulation of the central pain pathway and vascular functions. Clinical studies support its efficacy in reducing headache days, migraine hours, and related disability, with results comparable to those of established migraine treatments such as beta-blockers. Candesartan’s favorable cost profile, once-daily dosing, and good tolerability further support its potential as a first-line treatment option.</div></div><div><h3>Implications</h3><div>Candesartan offers a promising addition as an effective and safe option for migraine treatment, but further research is necessary. Future studies should focus on its use for acute attacks, dose-response relationships, long-term safety, and cost-effectiveness.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"47 9","pages":"Pages 807-812"},"PeriodicalIF":3.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Candesartan for Treatment of Migraine Headache: A Scoping Review\",\"authors\":\"Ena Elizabeth L. Naoe MD , Mykha Marie B. Tabuzo MD , Roland Dominic G. Jamora MD, PhD\",\"doi\":\"10.1016/j.clinthera.2025.06.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>Migraine is a prevalent and debilitating disorder, ranked as the third leading cause of global disability. Given its significant health and financial impact, exploring alternative treatments is crucial. Candesartan, an angiotensin-receptor blocker, has shown potential as a management for migraine.</div></div><div><h3>Methods</h3><div>A scoping review of literature on the efficacy and safety of candesartan in migraine treatment was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Scoping Reviews guidelines.</div></div><div><h3>Findings</h3><div>Thirty-eight articles were included in this review. Candesartan has shown promising results in preventing migraine, particularly in patients with comorbid conditions such as hypertension. Its mechanism may involve modulation of the central pain pathway and vascular functions. Clinical studies support its efficacy in reducing headache days, migraine hours, and related disability, with results comparable to those of established migraine treatments such as beta-blockers. Candesartan’s favorable cost profile, once-daily dosing, and good tolerability further support its potential as a first-line treatment option.</div></div><div><h3>Implications</h3><div>Candesartan offers a promising addition as an effective and safe option for migraine treatment, but further research is necessary. Future studies should focus on its use for acute attacks, dose-response relationships, long-term safety, and cost-effectiveness.</div></div>\",\"PeriodicalId\":10699,\"journal\":{\"name\":\"Clinical therapeutics\",\"volume\":\"47 9\",\"pages\":\"Pages 807-812\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0149291825002073\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0149291825002073","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

目的：偏头痛是一种普遍的使人衰弱的疾病，被列为全球致残的第三大原因。鉴于其对健康和经济的重大影响，探索替代疗法至关重要。坎地沙坦是一种血管紧张素受体阻滞剂，已显示出治疗偏头痛的潜力。方法：对坎地沙坦治疗偏头痛的有效性和安全性的文献进行范围综述，基于系统综述的首选报告项目和范围综述的荟萃分析指南。结果：本综述纳入了38篇文章。坎地沙坦在预防偏头痛方面显示出令人鼓舞的效果，特别是在患有高血压等合并症的患者中。其机制可能涉及中枢疼痛通路和血管功能的调节。临床研究支持其在减少头痛天数、偏头痛时间和相关残疾方面的功效，其结果与已建立的偏头痛治疗方法（如β受体阻滞剂）相当。坎地沙坦有利的成本、每日一次的剂量和良好的耐受性进一步支持了其作为一线治疗选择的潜力。结论：坎地沙坦作为一种有效且安全的偏头痛治疗选择，提供了一个很有希望的补充，但还需要进一步的研究。未来的研究应集中在其用于急性发作，剂量-反应关系，长期安全性和成本效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Candesartan for Treatment of Migraine Headache: A Scoping Review

Purpose

Migraine is a prevalent and debilitating disorder, ranked as the third leading cause of global disability. Given its significant health and financial impact, exploring alternative treatments is crucial. Candesartan, an angiotensin-receptor blocker, has shown potential as a management for migraine.

Methods

A scoping review of literature on the efficacy and safety of candesartan in migraine treatment was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Scoping Reviews guidelines.

Findings

Thirty-eight articles were included in this review. Candesartan has shown promising results in preventing migraine, particularly in patients with comorbid conditions such as hypertension. Its mechanism may involve modulation of the central pain pathway and vascular functions. Clinical studies support its efficacy in reducing headache days, migraine hours, and related disability, with results comparable to those of established migraine treatments such as beta-blockers. Candesartan’s favorable cost profile, once-daily dosing, and good tolerability further support its potential as a first-line treatment option.

Implications

Candesartan offers a promising addition as an effective and safe option for migraine treatment, but further research is necessary. Future studies should focus on its use for acute attacks, dose-response relationships, long-term safety, and cost-effectiveness.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical therapeutics 医学-药学

CiteScore

6.00

自引率

3.10%

发文量

154

审稿时长

9 weeks

期刊介绍： Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.